Healthy Returns: Eli Lilly, Novo Nordisk make progress toward boosting weight loss drug supply
Publishing timestamp: 2024-05-07 22:21:45
Summary
Eli Lilly and Novo Nordisk are making progress in increasing the supply of weight loss and diabetes drugs, with Eli Lilly receiving positive feedback from investors while Novo Nordisk's shares fell after missing sales estimates. Apple's heart-monitoring technology on the Apple Watch received approval from the FDA for use in clinical studies. Warren Buffett's stock portfolio is heavily invested in just 5 stocks.
Sentiment: MIXED
Tickers: LLY, NVO, AAPL, NOVO.B-DK,
Keywords: eli lilly and co, united states, apple inc, novo nordisk a/s, biotech and pharmaceuticals, david a. ricks, business news, health care industry,